贝特类药物与降低冠心病风险

Fibrates and coronary risk reduction.

作者信息

Steiner George

机构信息

Division of Endocrinology and Metabolism, Toronto General Hospital, 200 Elizabeth Street, University of Toronto, Toronto, Ontario, Canada M5G 2C4.

出版信息

Atherosclerosis. 2005 Oct;182(2):199-207. doi: 10.1016/j.atherosclerosis.2005.04.002.

DOI:10.1016/j.atherosclerosis.2005.04.002

PMID:15894321

Abstract

Many medications are currently available to correct lipoprotein abnormalities when lifestyle measures alone are not sufficient. No single agent or class of agents is able to correct all of the lipoprotein abnormalities. This paper reviews the role of one class, the fibrates, in the management of lipid disorders and summarizes the clinical trial information relating to their impact on coronary artery disease.

摘要

当仅靠生活方式干预不足以纠正脂蛋白异常时，目前有多种药物可供使用。没有单一药物或一类药物能够纠正所有脂蛋白异常。本文综述了一类药物（贝特类药物）在脂质紊乱管理中的作用，并总结了与其对冠状动脉疾病影响相关的临床试验信息。